Medindia

X

Talyst Moves Patient Safety and Inventory Control Beyond the Hospital

Sunday, December 7, 2008 General News J E 4
Advertisement
BELLEVUE, Wash., Dec. 7 Talyst, a leader in pharmacyautomation, today demonstrated InSite(TM), its innovative hardware andsoftware system designed to help central pharmacies provide unparalleledsupport for extended care environments with the use of remote dispensingtechnologies. The products were developed in response to hospital pharmacies'increasing need to implement safer, more cost-effective ways to service thelong-term care and correctional care environments they support.

InSite is being demonstrated this week at the American Society ofHealth-System Pharmacist (ASHP) Midyear Clinical Meeting in Orlando, FL.

"Talyst is committed to engineering a safer pharmacy in all healthcareenvironments. We have a strong history of delivering innovative automationsolutions to our hospital pharmacy customers, and InSite is a naturalextension of that innovation," noted Carla Corkern, chief executive officer ofthe company. "Talyst was the first to provide inventory and workflowmanagement control to all medication inventory locations, including supportfor multiple hospitals. With Talyst InSite, we are the first to extend thatcontrol to extended care environments managed by the hospital or integrateddelivery network."

A New Model for Remote Medication Management

The InSite Remote Dispensing System allows the central pharmacy to place asecure, automated medication dispensing unit at each facility they service.With InSite, medications are already at the facility and pharmacist-approvedmedication orders are immediately available for dispensing inpatient-specific, multi-dose packaging.

The innovative InSite system helps eliminate the need to createtime-consuming, waste-prone medication blister packs. It also enables fasterFirst Doses, gives nursing staff more time for other tasks, and allowsdown-to-the-dose accountability at each facility.

With centralized inventory monitoring, InSite requires far fewer scheduleddeliveries and special courier runs from the central pharmacy in order to meetthe changing needs of the facilities.

"Healthcare system pharmacies are increasingly looking for ways to improvethe safety and efficiency of their pharmacy operations beyond the traditionalin-patient settings," Corkern continued. "In a challenging economy, a growingnumber of hospital pharmacies are being asked to improve cost controls andfind new revenue sources. The InSite system improves the partnership betweencentral pharmacies and the facilities they support, and enables newopportunities for growth and safety improvements," she concluded.

About Talyst

Talyst is engineering a safer pharmacy. The company provides automatedsystems to hospitals, long-term care facilities and correctional facilities toimprove patient safety and dispensing accuracy while reducing costs andincreasing productivity. The Talyst solution uses innovative software and asuite of proven hardware components to package, barcode, store and trackmedication inventories.

Talyst is an award-winning company with more than 300 hospital andintegrated healthcare companies. The company is ranked in the "Inc. 500"national list of fastest-growing private companies, ranked number two on theDeloitte "Fast 50" Technology Companies in Washington State, and was listed asone of Fast Company magazine's "Fast 50 Reader Favorites", honoringinnovative, progressive enterprises.

For more information, call 877-4-Talyst (877-482-5978) or visitwww.talyst.com, www.talyst.com/ltc or see www.talyst.com/corrections.

Talyst and InSite are trademarks of Talyst Inc. Other trade names are theproperty of their respective owners.

SOURCE Talyst
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
University Hospitals Geneva Medical Center Registe...
S
Phase III Data Demonstrate Efficacy and Tolerabili...